Israel’s Rosetta Genomics has just had approval from the New Jersey Department of Health, for its OncoGxSelect diagnostic test for lung cancer. The test detects genetic mutations responsible for the tumors and help clinicians make relevant treatment decisions.

http://finance.yahoo.com/news/rosetta-genomics-expands-high-value-120000987.html